Security systems supplier Implant Sciences Corp (OTCQB:IMSC) said Monday that it has expanded both the global reach and sales of its new QS-B220 system, adding a new distributor in Switzerland.
This marks the company's first distributor in this country.
The new distributor has purchased a Quantum Sniffer QS-B220 system to use as a demonstration unit.
The QS-B220 is a desktop explosives and drugs trace detector that is
currently being evaluated for certification by the U.S. Transportation
Security Administration (TSA) for air cargo screening.
Introduced last year, the system is already deployed in Europe, the Middle East, Asia, and the Americas.
"The QS-B220's ease of use, ability to clear rapidly after detection,
and large color touch-screen are receiving growing attention from
security professionals worldwide," said Implant's VP of global sales and
marketing, Dr. Darryl Jones.
"Furthermore, in a world increasingly concerned about radiation safety, Implant Sciences' non-radioactive design is subject to far fewer regulations and restrictions than competing systems.
"We see a bright future for the QS-B220, one that will only get
brighter as we secure certifications from government regulatory agencies
around the world."
Earlier this month, the supplier of explosives trace detection
equipment announced it received a new patent in Russia covering a method
of increasing the amount of explosive materials collected from a
surface using the company's patented non-contact vortex attractor
Implant develops, manufactures and sells sensors and systems for security, safety, and defense (SS&D) markets.
Its other main device, the QS-H150 portable explosives trace
detector, has received Qualified Anti-Terrorism Technology designation.
The QS-B220 desktop explosives and drugs trace detector has received a
Developmental Testing & Evaluation (DT&E) designation by the
U.S. Department of Homeland Security.
Shares of the company advanced 3.2 per cent to close at $1.29 Monday.